202 related articles for article (PubMed ID: 32184588)
1. A Real-World Observational Study Examining the Impact of Aclidinium Bromide Therapy on the Quality of Life, Symptoms, and Activity Impairment of Patients with Chronic Obstructive Pulmonary Disease: The Greek ON-AIR Study.
Kostikas K; Vassilakopoulos TI; Tzanakis N; Konstantinidis AK; Kosmas EN; Papiris S; Steiropoulos P; Manali ED; Michaelides SA; Daskos G
Int J Chron Obstruct Pulmon Dis; 2020; 15():515-526. PubMed ID: 32184588
[TBL] [Abstract][Full Text] [Related]
2. Improvements in patient-reported outcomes: A prospective, non-interventional study with aclidinium bromide for treatment of COPD.
Marth K; Schuller E; Pohl W
Respir Med; 2015 May; 109(5):616-24. PubMed ID: 25796962
[TBL] [Abstract][Full Text] [Related]
3. The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies.
Jones PW; Leidy NK; Hareendran A; Lamarca R; Chuecos F; Garcia Gil E
Respir Res; 2016 May; 17(1):61. PubMed ID: 27215749
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.
Miravitlles M; Chapman KR; Chuecos F; Ribera A; Gil EG
Int J Chron Obstruct Pulmon Dis; 2016; 11():2041-53. PubMed ID: 27621610
[TBL] [Abstract][Full Text] [Related]
5. Clinical use of aclidinium in patients with COPD.
Reid DJ; Carlson AA
Int J Chron Obstruct Pulmon Dis; 2014; 9():369-79. PubMed ID: 24812502
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.
Jones PW; Rennard SI; Agusti A; Chanez P; Magnussen H; Fabbri L; Donohue JF; Bateman ED; Gross NJ; Lamarca R; Caracta C; Gil EG
Respir Res; 2011 Apr; 12(1):55. PubMed ID: 21518460
[TBL] [Abstract][Full Text] [Related]
7. Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study.
Beier J; Mroz R; Kirsten AM; Chuecos F; Gil EG
Int J Chron Obstruct Pulmon Dis; 2017; 12():1731-1740. PubMed ID: 28652725
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study.
Monteagudo M; Roset M; Rodriguez-Blanco T; Muñoz L; Miravitlles M
Int J Chron Obstruct Pulmon Dis; 2017; 12():1145-1152. PubMed ID: 28442901
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.
D'Urzo AD; Singh D; Donohue JF; Kerwin EM; Ribera A; Molins E; Chuecos F; Jarreta D; Gil EG
Int J Chron Obstruct Pulmon Dis; 2019; 14():479-491. PubMed ID: 30880938
[TBL] [Abstract][Full Text] [Related]
10. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Page CP; Matera MG
Expert Opin Pharmacother; 2013 Jun; 14(9):1205-14. PubMed ID: 23566013
[TBL] [Abstract][Full Text] [Related]
11. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.
Sethi S; Kerwin E; Watz H; Ferguson GT; Mroz RM; Segarra R; Molins E; Jarreta D; Garcia Gil E
Int J Chron Obstruct Pulmon Dis; 2019; 14():667-682. PubMed ID: 30962681
[TBL] [Abstract][Full Text] [Related]
12. Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease.
Jones PW
Int J Chron Obstruct Pulmon Dis; 2015; 10():677-87. PubMed ID: 25848244
[TBL] [Abstract][Full Text] [Related]
13. Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review.
Jones P
Adv Ther; 2013 Apr; 30(4):354-68. PubMed ID: 23553509
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
Kerwin EM; D'Urzo AD; Gelb AF; Lakkis H; Garcia Gil E; Caracta CF;
COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148
[TBL] [Abstract][Full Text] [Related]
16. A Real-World Study on the Day and Night-Time Symptoms Among Greek COPD Patients Who Recently Initiated Treatment with Dual Bronchodilation: The DANICO Study.
Kostikas K; Dimakou K; Gourgoulianis K; Gaga M; Papapetrou D; Tsoukalas G; Chatziapostolou P; Antoniadis A; Meletis G; Evangelopoulou E; Styliara P; Karypidou I; Gogali A; Kalafatakis K; Tzanakis N
Int J Chron Obstruct Pulmon Dis; 2022; 17():2027-2041. PubMed ID: 36072610
[TBL] [Abstract][Full Text] [Related]
17. Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.
Babu KS; Morjaria JB
Ther Adv Respir Dis; 2015 Apr; 9(2):56-68. PubMed ID: 25754881
[TBL] [Abstract][Full Text] [Related]
18. The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
Malerba M; Radaeli A; Santini G; Morjaria J; Mores N; Mondino C; Macis G; Montuschi P
Expert Opin Drug Discov; 2018 Jun; 13(6):563-577. PubMed ID: 29616842
[TBL] [Abstract][Full Text] [Related]
19. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants.
Jansat JM; Lamarca R; de Miquel G; Schrödter A; Miletzki B; Gurniak M
J Clin Pharmacol; 2009 Oct; 49(10):1239-46. PubMed ID: 19592595
[TBL] [Abstract][Full Text] [Related]
20. Effects of aclidinium on determinants of COPD severity: symptoms and quality of life.
Contoli M; Solidoro P; Di Marco F; Scichilone N; Corsico A; Braido F; Santus P
Int J Chron Obstruct Pulmon Dis; 2016; 11():3043-3050. PubMed ID: 27980401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]